#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Non-small cell lung cancer metastatic Asthma Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thrombotic microangiopathy Acute lymphocytic leukaemia Hyperinsulinaemic hypoglycaemia Gastric cancer Small cell lung cancer limited stage Primary myelofibrosis Eosinophilic granulomatosis with polyangiitis Hereditary spastic paraplegia Glomerulonephritis rapidly progressive Immunodeficiency common variable Retinal dystrophy Neuroblastoma Stargardt's disease Fusarium infection Wiskott-Aldrich syndrome More trials…

    Learn about Rare Diseases

    Progressive multifocal leukoencephalopathy – Life with Disease Brain stem glioma – Basic Information Mitochondrial myopathy Mucopolysaccharidosis – Diagnostics Pemphigus Small intestine leiomyosarcoma – Trials in Disease Fabry’s disease – Basic Information Systemic sclerosis pulmonary – Basic Information Brain stem glioma – Life with Disease Idiopathic inflammatory myopathy – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lithium VTX2735 SODIUM GSKVX000000039711 Gsk4381562A Esmolol Hydrochloride Dexamethasone Ph. Eur. Autologous Chondrocytes Volrustomig Tocilizumab Tasquinimod Ly3298176 Daunorubicin Hydrochloride Allo-647 Floxuridine Lapatinib Esflurbiprofen Ketotifen Hydrogen Fumarate Alprazolam Duloxetine Axicabtagene Ciloleucel More therapies…

    Learn about Your Condition

    Systemic lupus erythematosus Partial lipodystrophy Cutaneous calcification Small intestine carcinoma Lichen planus Bacteraemia Axial spondyloarthritis Neonatal respiratory failure Staphylococcal infection Vulvovaginal discomfort Pneumothorax Affective disorder Mixed dementia Ischaemic skin ulcer Bronchitis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Psoriasis

  • A study to evaluate the effectiveness and safety of zasocitinib in children and adolescents with moderate-to-severe plaque psoriasis

    Recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Zasocitinib
    Germany Italy Poland Spain

  • Long-term safety study of deucravacitinib compared to ustekinumab in adults with moderate to severe plaque psoriasis

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Deucravacitinib
    • Ustekinumab
    Belgium Bulgaria Czechia Denmark France Germany +6

  • Study of deucravacitinib compared to placebo in adolescents aged 12-17 years with moderate to severe plaque psoriasis

    Recruiting

    3 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Deucravacitinib
    Belgium Germany Hungary Italy Poland Romania +1

  • Study on Sodium Fluoride (18F) PET-CT Scans for Detecting Bone Changes in Psoriasis Patients at Risk of Psoriatic Arthritis

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Sodium Fluoride (18F)
    The Netherlands

  • Study on Proactive Drug Monitoring with Secukinumab, Ixekizumab, or Guselkumab for Patients with Moderate-to-Severe Psoriasis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    Investigated Drugs:
    • Ixekizumab
    • Guselkumab
    • Secukinumab
    Belgium

  • Study on the Safety and Immune Response of Shingrix Vaccine in Patients with Psoriasis or Psoriatic Arthritis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Psoriasis
    • Psoriatic arthropathy
    Investigated Drugs:
    • Recombinant Varicella Zoster Virus Glycoprotein E
    Germany
1 2 3 … 9
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!